either with etanercept (ETA, 10 mg/kg), an anti-mouse TNF antibody (MP6-XT22, rat IgG1, 10 mg/kg) or an anti-human IL17 antibody (secukinumab, SEC, 10 mg/kg) as a control. Daily clinical evaluation of K/BxN serum induced-arthritis was performed in 3TG as well as WT mice. Polarization of bone marrow-derived macrophages (BMDM) and cytokine production from non-arthritic WT and 3TG mice under the action of anti-TNF *in vitro* was evaluated by RT-qPCR, CBA and ELISA.

Results *In vivo*, the administration of anti-TNF (ETA or MP6-XT22) decreased arthritic scores in WT mice ($p=0.005$) as well as in 3TG mice ($p<0.001$), unlike SEC which had no effect, proving that anti-TNF binding of tmTNF decreased arthritis. *In vitro* effect of anti-TNF on BMDM from WT as well as 3TG mice induced a decrease in the expression of genes specific of inflammatory macrophages (CD38, GpR18 and FpR2), and an increase in the expression of genes specific of alternative macrophages (Arg1, EgR2, c-Myc). We also observed an inhibition of the secretion of pro-inflammatory cytokines (IL12p70 and IL-6) and an early peak of IL-10 secretion demonstrating an effect of reverse signaling on macrophage polarization and activation. This suggested a switch in macrophage polarization as a probable mechanism for modulation of inflammation during K/BxN serum-induced arthritis.

Conclusions Our work provides *in vivo* evidence for the involvement of reverse signaling in the anti-TNF-mediated modulation of arthritis. Reverse signaling is expected to result in the modulation of macrophage polarization from an inflammatory to an alternative functional phenotype in arthritic mice. Our data prompt us to consider new interpretation of the effects of anti-TNF in the treatment of RA.

Disclosure of Interest None declared.

P039/003 CIRCULATING FOLLICULAR HELPER T CELLS ARE INCREASED IN SYSTEMIC SCLEROSIS AND PROMOTE PLASMABLAST DIFFERENTIATION THROUGH THE IL-21 PATHWAY WHICH CAN BE INHIBITED BY RUXOLITINIB

¹L Ricard*, ¹V Jachiet, ²F Malard, ¹Y Ye, ¹N Stocker, ³S Rivière, ⁴P Senet, ⁴J-B Monfort, ³O Fain, ²M Mohty, ¹B Gaugler, ³A Mekinian. ¹Centre de recherche Saint-Antoine, INSERM; ²Hématologie; ³Médecine Interne, Hôpital Saint-Antoine; ⁴Dermatologie, Hôpital Tenon, Paris, France

10.1136/annrheumdis-2018-EWRR2019.31

Career situation of first and presenting author Student for a master or a PhD

Introduction Systemic sclerosis (SSc) is an autoimmune disease characterized by widespread fibrosis, microangiopathy and autoantibodies. Follicular helper T (Tfh) cells CD4⁺CXCR5⁺PD-1⁺ cooperate with B lymphocytes to induce the differentiation of plasmocytes secreting Immunoglobulins (Ig). Circulating Tfh (cTfh) cells are increased in several autoimmune diseases.¹ Tfh cells can infiltrate the skin of SSc patients, and induce fibrosis *in vitro*.²

Objectives The aim of this study was to perform a quantitative and functional analysis of cTfh cells in SSc.

Methods Using flow cytometry, we analyzed cTfh cells from 52 SSc patients with no immunomodulatory treatment and 38 healthy controls (HC). *In vitro* coculture experiments of sorted cTfh and B cells from 13 SSc patients and 6 HC were performed for functional analysis. IgG and IgM production were measured by ELISA. BCL-6, Blimp-1, CXCL13 and IL-21 expression were analyzed by RTqPCR.

Results We observed that cTfh cell numbers are increased in SSc patients compared with HC. Furthermore, the increase in cTfh cells was more potent in patients with severe forms of SSc such as diffuse SSc and in the presence of arterial pulmonary hypertension. cTfh cells from SSc patients present an activated Tfh phenotype, with high expression of BCL-6 and increased capacity to produce IL-21 in comparison to HC. *In vitro*, cTfh cells from SSc patients had higher capacity to stimulate the differentiation of CD19⁺CD27⁺CD38^{hi} B cells and their secretion of IgG and IgM through the IL-21 pathway than cTfh cells from HC. Blocking IL-21 or using the JAK1/2 inhibitor ruxolitinib reduced the Tfh cells' capacity to stimulate the plasmablasts and Ig production.

Conclusions Circulating Tfh cells are increased in SSc and correlate with SSc severity. The IL-21 pathway or JAK1/2 blockade by ruxolitinib could be a promising strategy in the treatment of SSc.

REFERENCES

1. Crotty S. T follicular helper cell differentiation, function, and roles in disease. *Immunity* 2014;41(4):529-42.
2. Taylor DK, Mittereder N, Kuta E, Delaney T, Burwell T, Dacosta K, *et al*. T follicular helper-like cells contribute to skin fibrosis. *Sci Transl Med* 2018;10(431).

Acknowledgements This work was supported by the Aterhit foundation and received grants from 'Groupe Francophone de Recherche sur la Sclérodémie' (GFRS).

Disclosure of Interest None declared

P040

THE EUROPEAN CONSENSUS FINDING STUDY GROUP ON AUTOANTIBODIES 2017/18 INVESTIGATION. CHARACTERISATION OF AUTOANTIBODY CONTENT IN A NEW INTERNATIONAL REFERENCE STANDARD FOR DENSE FINE SPECKLED 70KD (DFS70) AUTOANTIBODIES

¹J Rönnelid*, ²M Blüthner, ³C Dahle, ⁴L Andrade, ⁵E Feist, ⁶D Hamann, on behalf of The European Consensus Finding Study Group on autoantibodies (ECFSG)*. ¹Uppsala Univ, Dept Immunol, Genet and Pathol, Uppsala, Sweden; ²Laboratory Volkmann, Karlsruhe, Germany; ³Linköping Univ, Dept Clin Exp Med, Linköping, Sweden; ⁴Dept Rheumatol, São Paulo Univ, São Paulo, Brazil; ⁵Charité, Dept Rheumatol Clin Immunol, Berlin, Germany; ⁶Utrecht Univ, LTI Diagnostics, Utrecht, Netherlands

10.1136/annrheumdis-2018-EWRR2019.32

Career situation of first and presenting author Instructor.

Introduction The European Consensus Finding Study Group on autoantibodies (ECFSG) a.k.a. the EULAR autoantibody study group has been active for 30 years.

Objectives To reach consensus about autoantibody measurements in clinical practice, and to evaluate upcoming autoantibody standard reagents concerning autoantibody content.

Methods ECFSG focus on evaluating difficult to interpret serum samples, where differences between assays can be clearly visible. Ten unknown samples are distributed yearly to European laboratories, and analyzed broadly. Results are collected with information about laboratory techniques used, and discussed in relation to clinical information on the donating patients during EWRR. The 2017/2018 investigation contained nine patient samples, and a not yet launched pooled standard for anti-dense fine speckled 70kD antibodies, an ANA reactivity with specific nuclear staining on HEp-2 cells that can be confounded with homogenous ANA, but that is not associated with autoimmune disease.

Results Acceptable consensus was reached for the clinical samples. Anti-DFS70 pattern was reported from 32/38